A myocardialis ossejt kezelés jelenlegi gyakorlata és távlatai

László Balogh, I. Czuriga, Éva Kristóf, I. Édes

Research output: Article

1 Citation (Scopus)

Abstract

Myocardial infarction became more frequent mainly in the developed countries in the past decades. Beside the pharmacological (thrombolysis, beta-blockers, ACE-inhibitors, antiplatelet-and lipid-lowering drugs, etc.) and interventional (percutaneous coronary intervention, intraaortic ballon pump, resyncronising therapy, left ventricular assist devices etc.) procedures the quality of life of patients and the morbidity and mortality data were improved. However we experience development of heart failure following myocardial infarction because of significant cell loss and left ventricular remodeling. Until now there wasn't any therapeutic procedure affecting via cardiomyocyte renewal, but in the last 5 years the myocardial stem cell therapy was introduced to human clinical phase. In this review the authors summarized the general features of stem cells, why these cells are in the focus of the interest and their preclinical and clinical applications in myocardial infarction. Promising issues suggests, that intramyocardial implantation of autologous bone marrow derived stem cells become a new therapeutic modality in treatment of myocardial infarction. The stem cell therapy and regenerative medicine would open new perspectives in cardiology. However it is very important to remark, that this, as every medical procedure can be dangerous and can cause side effects. A lot of molecular and cellular mechanism of cell therapy is not clear at present, that's why we should be careful with this opportunity holding in our hands. We have to plan multicenter clinical trials to evaluate the long term safety and efficacy of the procedure.

Original languageHungarian
Pages (from-to)1110-1120
Number of pages11
JournalOrvosi Hetilap
Volume146
Issue number20 SUPPL. 2
Publication statusPublished - 2005

Fingerprint

Cell- and Tissue-Based Therapy
Stem Cells
Myocardial Infarction
Ventricular Remodeling
Heart-Assist Devices
Regenerative Medicine
Percutaneous Coronary Intervention
Therapeutics
Cardiology
Angiotensin-Converting Enzyme Inhibitors
Developed Countries
Cardiac Myocytes
Multicenter Studies
Heart Failure
Bone Marrow
Quality of Life
Clinical Trials
Pharmacology
Morbidity
Lipids

Keywords

  • Heart failure
  • Myocardialis infarctus
  • Stem cell therapy

ASJC Scopus subject areas

  • Medicine(all)

Cite this

A myocardialis ossejt kezelés jelenlegi gyakorlata és távlatai. / Balogh, László; Czuriga, I.; Kristóf, Éva; Édes, I.

In: Orvosi Hetilap, Vol. 146, No. 20 SUPPL. 2, 2005, p. 1110-1120.

Research output: Article

Balogh, L, Czuriga, I, Kristóf, É & Édes, I 2005, 'A myocardialis ossejt kezelés jelenlegi gyakorlata és távlatai', Orvosi Hetilap, vol. 146, no. 20 SUPPL. 2, pp. 1110-1120.
Balogh, László ; Czuriga, I. ; Kristóf, Éva ; Édes, I. / A myocardialis ossejt kezelés jelenlegi gyakorlata és távlatai. In: Orvosi Hetilap. 2005 ; Vol. 146, No. 20 SUPPL. 2. pp. 1110-1120.
@article{3d2316fa0a4c46a9b46d7f903a7cfa79,
title = "A myocardialis ossejt kezel{\'e}s jelenlegi gyakorlata {\'e}s t{\'a}vlatai",
abstract = "Myocardial infarction became more frequent mainly in the developed countries in the past decades. Beside the pharmacological (thrombolysis, beta-blockers, ACE-inhibitors, antiplatelet-and lipid-lowering drugs, etc.) and interventional (percutaneous coronary intervention, intraaortic ballon pump, resyncronising therapy, left ventricular assist devices etc.) procedures the quality of life of patients and the morbidity and mortality data were improved. However we experience development of heart failure following myocardial infarction because of significant cell loss and left ventricular remodeling. Until now there wasn't any therapeutic procedure affecting via cardiomyocyte renewal, but in the last 5 years the myocardial stem cell therapy was introduced to human clinical phase. In this review the authors summarized the general features of stem cells, why these cells are in the focus of the interest and their preclinical and clinical applications in myocardial infarction. Promising issues suggests, that intramyocardial implantation of autologous bone marrow derived stem cells become a new therapeutic modality in treatment of myocardial infarction. The stem cell therapy and regenerative medicine would open new perspectives in cardiology. However it is very important to remark, that this, as every medical procedure can be dangerous and can cause side effects. A lot of molecular and cellular mechanism of cell therapy is not clear at present, that's why we should be careful with this opportunity holding in our hands. We have to plan multicenter clinical trials to evaluate the long term safety and efficacy of the procedure.",
keywords = "Heart failure, Myocardialis infarctus, Stem cell therapy",
author = "L{\'a}szl{\'o} Balogh and I. Czuriga and {\'E}va Krist{\'o}f and I. {\'E}des",
year = "2005",
language = "Hungarian",
volume = "146",
pages = "1110--1120",
journal = "Orvosi Hetilap",
issn = "0030-6002",
publisher = "Akademiai Kiado",
number = "20 SUPPL. 2",

}

TY - JOUR

T1 - A myocardialis ossejt kezelés jelenlegi gyakorlata és távlatai

AU - Balogh, László

AU - Czuriga, I.

AU - Kristóf, Éva

AU - Édes, I.

PY - 2005

Y1 - 2005

N2 - Myocardial infarction became more frequent mainly in the developed countries in the past decades. Beside the pharmacological (thrombolysis, beta-blockers, ACE-inhibitors, antiplatelet-and lipid-lowering drugs, etc.) and interventional (percutaneous coronary intervention, intraaortic ballon pump, resyncronising therapy, left ventricular assist devices etc.) procedures the quality of life of patients and the morbidity and mortality data were improved. However we experience development of heart failure following myocardial infarction because of significant cell loss and left ventricular remodeling. Until now there wasn't any therapeutic procedure affecting via cardiomyocyte renewal, but in the last 5 years the myocardial stem cell therapy was introduced to human clinical phase. In this review the authors summarized the general features of stem cells, why these cells are in the focus of the interest and their preclinical and clinical applications in myocardial infarction. Promising issues suggests, that intramyocardial implantation of autologous bone marrow derived stem cells become a new therapeutic modality in treatment of myocardial infarction. The stem cell therapy and regenerative medicine would open new perspectives in cardiology. However it is very important to remark, that this, as every medical procedure can be dangerous and can cause side effects. A lot of molecular and cellular mechanism of cell therapy is not clear at present, that's why we should be careful with this opportunity holding in our hands. We have to plan multicenter clinical trials to evaluate the long term safety and efficacy of the procedure.

AB - Myocardial infarction became more frequent mainly in the developed countries in the past decades. Beside the pharmacological (thrombolysis, beta-blockers, ACE-inhibitors, antiplatelet-and lipid-lowering drugs, etc.) and interventional (percutaneous coronary intervention, intraaortic ballon pump, resyncronising therapy, left ventricular assist devices etc.) procedures the quality of life of patients and the morbidity and mortality data were improved. However we experience development of heart failure following myocardial infarction because of significant cell loss and left ventricular remodeling. Until now there wasn't any therapeutic procedure affecting via cardiomyocyte renewal, but in the last 5 years the myocardial stem cell therapy was introduced to human clinical phase. In this review the authors summarized the general features of stem cells, why these cells are in the focus of the interest and their preclinical and clinical applications in myocardial infarction. Promising issues suggests, that intramyocardial implantation of autologous bone marrow derived stem cells become a new therapeutic modality in treatment of myocardial infarction. The stem cell therapy and regenerative medicine would open new perspectives in cardiology. However it is very important to remark, that this, as every medical procedure can be dangerous and can cause side effects. A lot of molecular and cellular mechanism of cell therapy is not clear at present, that's why we should be careful with this opportunity holding in our hands. We have to plan multicenter clinical trials to evaluate the long term safety and efficacy of the procedure.

KW - Heart failure

KW - Myocardialis infarctus

KW - Stem cell therapy

UR - http://www.scopus.com/inward/record.url?scp=22144488124&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=22144488124&partnerID=8YFLogxK

M3 - Article

C2 - 15945240

AN - SCOPUS:22144488124

VL - 146

SP - 1110

EP - 1120

JO - Orvosi Hetilap

JF - Orvosi Hetilap

SN - 0030-6002

IS - 20 SUPPL. 2

ER -